Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons. Its portfolio includes orthobiologics for bone healing as well as spinal implants and instrumentation, sold primarily in the United States and also through international distribution channels.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBiologic products used to support bone growth and healing in spine and orthopedic procedures.
Implants, fixation systems, and surgical instrumentation used in spinal disease treatment.
Human tissue-based products including bone matrices and amniotic membrane allografts.
Products
Reported · share of revenue- Orthobiologics54.3 %
- Spinal Implant31.5 %
- License Revenue13.9 %
- Bill and Hold Transactions0.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Xtant sells to orthopedic and neurological surgeons through independent distributors, stocking agents, and direct employees. Its products are also accessed through national accounts, integrated delivery networks, and group purchasing organizations, which matter because hospital systems influence product selection and purchasing access.
Buy orthobiologics and graft products to support bone healing in surgical procedures.
Buy spinal implants, fixation systems, and instrumentation for spine surgery.
Purchase and place products into accounts, helping drive surgeon adoption and hospital access.
Provide purchasing access and contracting leverage for hospitals and surgical networks.
Distribute products in Europe, Canada, Mexico, South America, Australia, and Pacific markets.
Strategy
Xtant is focused on expanding its product portfolio, broadening distribution, and entering adjacent markets around spine and regenerative medicine. It also seeks to use technology and strategic transactions to extend its platform, which can reshape its product mix and market access over time.
Fresh products help defend surgeon relationships and expand use cases in spine and orthobiologics.
A broader channel footprint improves access to hospitals, surgeons, and regional accounts.
Moving into related surgical categories can increase wallet share with existing customers.
Deals can add products, technology, or distribution reach without building everything internally.
Geography
Q1/2026The company is centered on the United States, where it sells through independent agents, stocking distributors, and national accounts. It also promotes products internationally through direct representatives and distribution partners in Europe, Canada, Mexico, South America, Australia, and certain Pacific region countries, which broadens market reach but adds channel and regulatory complexity.
Share of the revenue the company reports by geography.
Risks
Xtant faces execution risk from product launches, channel dependence, and the complexity of selling through distributors, GPOs, and IDNs. The company also has transaction-related risk from pending asset sales, plus financing and liquidity risk because it may need additional capital to support operations and strategy.
- Pending sale of Coflex/CoFix and international hardware businessImpact: HighLikelihood: Medium
The transactions may be delayed, fail to close, or distract management and disrupt customers and suppliers.
Exposure: Core business relationships and operating continuity
- Need for additional financingImpact: HighLikelihood: Low
The company may require capital before expected cash resources are exhausted, and terms may be unfavorable.
Exposure: Liquidity and strategic flexibility
- Regulatory and reimbursement pressureImpact: MediumLikelihood: High
Medical device and biologics businesses depend on approvals, compliance, and payer acceptance.
Exposure: Spine and regenerative medicine markets
- Channel concentration and distributor dependenceImpact: MediumLikelihood: Low
Sales rely heavily on independent agents and stocking distributors, which can affect coverage and pricing control.
Exposure: U.S. commercial execution
- Product adoption and launch riskImpact: Medium
New biologics and spine systems must gain surgeon acceptance and hospital access to scale.
Exposure
Accounting
Judgemental itemsDistributor, stocking, and hospital sales may have different recognition triggers and return provisions.
Impact: Affects quarterly revenue timing and comparability
Pending asset sales and strategic transactions require judgment on asset disposal, gains/losses, and related costs.
Impact: Can materially affect reported operating results
Borrowings under credit facilities drive interest expense and may include covenant-related judgments.
Impact: Affects net income and liquidity analysis
Medical device and biologics assets may require impairment testing if performance changes.
Impact: Could create non-cash charges to earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Axogen, Inc.
AXGN · Electromedical & Electrotherapeutic Apparatus
Organogenesis Holdings Inc.
ORGO · Pharmaceutical Preparations
Regenerative Medical Technology Group Inc.
RMTG · Retail-Retail Stores, NEC
Integra LifeSciences Holdings Corporation
IART · Surgical & Medical Instruments & Apparatus
Zimmer Biomet Holdings, Inc
ZBH · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Zimmer Biomet Holdings is a U.S.-based medical technology company focused on orthopedic reconstruction and related surgical care.
Last updated: 24/09/2026